ROCO
6621
Market cap14mUSD
Oct 08, Last price
12.40TWD
1D
-1.20%
1Q
6.90%
IPO
-53.52%
Name
Uni Pharma Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
UniPharma Co., Ltd. is a Taiwanese enterprise specializing in the distribution of pharmaceuticals, medical apparatus, and diagnostic kits. Its diagnostic portfolio encompasses various medical disciplines, including oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. The company's offerings feature products such as Adept reduction solution, anesthetic injections (including bain, esmolol HCI, and naloxone), the Elisa DR-70 test for in-vitro tumor detection, and Fomeject antidote injections. Furthermore, UniPharma extends its services to include drug development, research and development, clinical studies, and marketing. Its client base includes major medical centers, regional hospitals, and local clinics. Founded in 1998, UniPharma is headquartered in Taipei, Taiwan.
Key people
Huiling Chen
Chief Financial Officer · since 2020
Liangguang Lin
General Manager
Qiaolei Zheng
Acting Deputy General Manager · since 2024
Peishan Zhang
Head of Finance & Accounting · since 2025
Zheng Chen
Chairman of the Board
Heying Jian
Independent Director
Jialin Wang
Independent Director
Mingjuan Xie
Independent Director
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||